ReviewVirologica Sinica2020
Summary of the Detection Kits for SARS-CoV-2 Approved by the National Medical Products Administration of China and Their Application for Diagnosis of COVID-19.
Review in Virologica Sinica, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed, 1 synthesis or guideline pooled it, 37 citations in OpenAlex.
- Accuracy of novel antigen rapid diagnostics for SARS-CoV-2: A living systematic review and meta-analysis.PLoS medicine · 2021Pooled it
- Development of paper-based electrochemiluminescence test strips for pathogenic microorganisms.BMC infectious diseases · 2025Article
- A Mechanical Assay for the Quantification of Anti-RBD IgG Levels in Finger-Prick Whole Blood.ACS sensors · 2023Article
- Evaluation of a Sample-to-Result POCKIT Central SARS-CoV-2 PCR System.Diagnostics (Basel, Switzerland) · 2023Article
- Molecular Diagnostic Tools against SARS-CoV-2 in Poland in 2022.Biomedicines · 2022Review
- Novel bridge multi-species ELISA for detection of SARS-CoV-2 antibodies.Journal of immunological methods · 2022Article
- Safety and immunogenicity of inactivated COVID-19 vaccination in adult rheumatic patients in South China: a prospective study.Human vaccines & immunotherapeutics · 2022Article
- Comparison of the performance of two real-time fluorescent quantitative PCR kits for the detection of SARS-CoV-2 nucleic acid: a study based on large real clinical samples.Virology journal · 2022Article
- Preparation of the luciferase-labeled antibody for improving the detection sensitivity of viral antigen.Virology journal · 2022Article
- Microfluidic particle dam for direct visualization of SARS-CoV-2 antibody levels in COVID-19 vaccinees.Science advances · 2022Article
- Development of a rapid neutralizing antibody test for SARS-CoV-2 and its application for neutralizing antibody screening and vaccinated serum testing.Infectious medicine · 2022Article
- SARS-CoV-2 Molecular Diagnostics in China.Clinics in laboratory medicine · 2022Review
- Denaturing and dNTPs reagents improve SARS-CoV-2 detectionF1000Research · 2022Article
- Monoplex and multiplex immunoassays: approval, advancements, and alternatives.Comparative clinical pathology · 2022Review
- A Pilot Study of 0.4% Povidone-Iodine Nasal Spray to Eradicate SARS-CoV-2 in the Nasopharynx.Infection and drug resistance · 2022Article
- Ten Years of Lateral Flow Immunoassay Technique Applications: Trends, Challenges and Future Perspectives.Sensors (Basel, Switzerland) · 2021Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The on-going global pandemic of coronavirus disease 2019 (COVID-19) caused by a novel coronavirus called severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has been underway for about 11 months. Through November 20, 2020, 51 detection kits for SARS-CoV-2 nucleic acids (24 kits), antibodies (25 kits), or antigens (2 kits) have been approved by the National Medical Products Administration of China (NMPA). Convenient and reliable SARS-CoV-2 detection assays are urgently needed worldwide for strategic control of the pandemic. In this review, the detection kits approved in China are summarised and the three types of tests, namely nucleic acid, serological and antigen detection, which are available for the detection of COVID-19 are discussed in detail. The development of novel detection kits will lay the foundation for the control and prevention of the COVID-19 pandemic globally.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.